1. Home
  2. UTL vs TBPH Comparison

UTL vs TBPH Comparison

Compare UTL & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UNITIL Corporation

UTL

UNITIL Corporation

HOLD

Current Price

$51.73

Market Cap

906.9M

Sector

Utilities

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.34

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UTL
TBPH
Founded
1984
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
906.9M
824.9M
IPO Year
1995
2013

Fundamental Metrics

Financial Performance
Metric
UTL
TBPH
Price
$51.73
$16.34
Analyst Decision
Buy
Buy
Analyst Count
2
6
Target Price
$56.50
$18.40
AVG Volume (30 Days)
82.8K
282.6K
Earning Date
05-04-2026
05-04-2026
Dividend Yield
3.65%
N/A
EPS Growth
1.37
279.13
EPS
1.85
N/A
Revenue
$536,000,000.00
$15,386,000.00
Revenue This Year
$5.43
$8.46
Revenue Next Year
$4.22
N/A
P/E Ratio
$27.78
N/A
Revenue Growth
8.33
N/A
52 Week Low
$45.11
$9.10
52 Week High
$55.12
$21.03

Technical Indicators

Market Signals
Indicator
UTL
TBPH
Relative Strength Index (RSI) 50.99 46.74
Support Level $51.05 $16.14
Resistance Level $53.65 $17.21
Average True Range (ATR) 1.20 0.38
MACD 0.13 -0.07
Stochastic Oscillator 62.30 29.31

Price Performance

Historical Comparison
UTL
TBPH

About UTL UNITIL Corporation

Unitil Corp through its subsidiaries engages in the distribution of electricity and natural gas in its service territories in the states of New Hampshire, Massachusetts and Maine. Its natural gas operations include gas distribution utility operations and interstate gas transmission pipeline operations. It also engages in interstate natural gas transmission pipeline company, operating approximately 85 miles of underground gas transmission pipeline located in Maine and New Hampshire. The company's segments include Electric and Gas.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: